menu
    • menu
    [{"orgOrder":0,"company":"University of Magdeburg","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Magdeburg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Magdeburg \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"University of Magdeburg \/ Bayer AG"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"DPT Laboratories, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Padagis \/ DPT Laboratories, Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ DPT Laboratories, Ltd"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Wake Forest University Health Sciences \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Wake Forest University Health Sciences \/ Bayer AG"},{"orgOrder":0,"company":"Clinical Research Center of the Carolinas","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"Clinical Research Center of the Carolinas","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Clinical Research Center of the Carolinas \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Clinical Research Center of the Carolinas \/ Bayer AG"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm Research \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Marco Alexandre Dias da Rocha","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Marco Alexandre Dias da Rocha","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Marco Alexandre Dias da Rocha"}]

    Find Clinical Drug Pipeline Developments & Deals for Azelaic Acid

    Menu

    Azelaic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 28, 2018

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Clinical Research Center of the Carolinas

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Clinical Research Center of the Carolinas

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2018

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Actavis Inc

                            Ireland arrow
                            Neuroscience
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants W...

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2017

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2017

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Padagis

                            Israel arrow
                            Neuroscience
                            Not Confirmed

                            Padagis

                            Israel arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : DPT Laboratories, Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 15, 2016

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : DPT Laboratories, Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Derm Research

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Derm Research

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2014

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actavis Inc

                            Ireland arrow
                            Neuroscience
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Ros...

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2014

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bayer AG

                            Germany arrow
                            Neuroscience
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Marco Alexandre Dias da Rocha

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Influence of Peripheral Androgen Conversion at Women Adult Acne

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 09, 2013

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Marco Alexandre Dias da Rocha

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Wake Forest University Health Sciences

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Wake Forest University Health Sciences

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination Gel and Vascular ND in Mild to Moderate Rosacea

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2012

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Leo Pharma

                            Denmark arrow
                            Neuroscience
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

                            Details : Azelaic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2012

                            Lead Product(s) : Azelaic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth